Publicaciones en las que colabora con DAVID SANZ ROSA (17)

2024

  1. Hypofractionated whole breast IMRT with HDR brachytherapy boost in early-stage breast cancer: Long-term results from a single-center

    Brachytherapy

2023

  1. Jorge clinical study: 10-year outcomes of risk-adapted radiotherapy defined by multiparametric MRI for prostate cancer

    World Journal of Urology, Vol. 41, Núm. 12, pp. 3829-3838

2021

  1. Breast cancer radiotherapy: What physicians need to know in the era of the precision medicine

    Breast Disease, Vol. 40, Núm. 1, pp. 1-16

2020

  1. High-dose neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery in potentially-resectable stage IIIA-N2 NSCLC. A multi-institutional retrospective study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

    Reports of Practical Oncology and Radiotherapy, Vol. 25, Núm. 3, pp. 447-455

  2. Impact of 68Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain

    Reports of Practical Oncology and Radiotherapy, Vol. 25, Núm. 3, pp. 405-411

2019

  1. Multiparametric magnetic resonance imaging-guided salvage radiotherapy in prostate cancer

    Reports of Practical Oncology and Radiotherapy, Vol. 24, Núm. 5, pp. 472-480

  2. Preoperative diagnosis of atypical pelvic leiomyoma and sarcoma: the potential role of diffusion-weighted imaging

    Journal of Obstetrics and Gynaecology, Vol. 39, Núm. 1, pp. 98-104

  3. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

    Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 735-744

2018

  1. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society)

    Lung Cancer, Vol. 118, pp. 119-127

  2. Response to: Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC- ain't no mountain high enough…. to keep me getting to you by Jeremic Branislav

    Lung Cancer

2016

  1. Endorectal magnetic resonance imaging for risk classification of localized prostate cancer: Radiographic findings and influence on treatment decisions

    Urologic Oncology: Seminars and Original Investigations

  2. Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: A single center experience

    Cancer Imaging, Vol. 16, Núm. 1

  3. Letter by Couñago et al. regarding article “Impact of multiparametric magnetic resonance imaging on risk group assessment of patients with prostate cancer addressed to external beam radiation therapy”

    European Journal of Radiology

  4. Negligencia auditiva en pacientes con enfermedad de Alzheimer

    AUDITIO, Vol. 4, Núm. 3, pp. 63-66

2015

  1. Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy

    SpringerPlus, Vol. 4, Núm. 1, pp. 1-8

2014

  1. Response to letter regarding article, "effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial"

    Circulation

2013

  1. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The effect of Metoprolol in Cardioprotection during an Acute Myocardial Infarction (METOCARD-CNIC) Trial

    Circulation, Vol. 128, Núm. 14, pp. 1495-1503